视路与下丘脑胶质瘤的临床结局:一项20年单中心回顾性研究
该单中心回顾性研究纳入1999年2月至2019年7月在首尔大学儿童医院治疗的47例视路与下丘脑胶质瘤患者,中位年龄6.9岁,化疗为所有患者一线治疗。5年总生存率为97.7%,5年无进展生存率为47.7%。作者认为以微创手术和化疗作为一线治疗的管理策略可行。
要点
- 47例视路与下丘脑胶质瘤患者中,32例(68%)以化疗为一线治疗。
- 5年总生存率为97.7%,5年无进展生存率为47.7%。
- 作者认为以微创手术和化疗作为一线治疗的管理策略可行。
核心结论
- 采用微创手术和化疗作为一线治疗管理视路与下丘脑胶质瘤是可行的。
- 对于存在脑脊液通路梗阻、化疗或放疗后进展以及难治性分流相关腹水的视路与下丘脑胶质瘤患者,可考虑行减瘤手术。
研究设计与样本
- 单中心回顾性研究,纳入1999年2月至2019年7月在首尔大学儿童医院接受治疗的47例视路与下丘脑胶质瘤患者。
- 采用多学科方法确定治疗方案,化疗为所有患者的一线治疗。
- 存在脑积水症状时行减瘤手术以恢复脑脊液循环。
主要发现
- 平均年龄6.9岁,3例诊断为1型神经纤维瘤病。
- 切除程度:无切除或活检13例(28%),部分切除23例(49%),次全至全切除11例(23%)。
- 32例(68%)患者以化疗为一线治疗。
- 脑室腹腔分流术后腹水3例,其中2例经减瘤手术成功处理。
- 5年总生存率为97.7%,5年无进展生存率为47.7%。
临床怎么用
- 作者认为以微创手术和化疗作为一线治疗管理视路与下丘脑胶质瘤是可行的。
- 作者建议对存在脑脊液通路梗阻、化疗或放疗后进展以及难治性分流相关腹水的视路与下丘脑胶质瘤患者可考虑行减瘤手术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optic pathway and hypothalamic gliomas (OPHGs) are challenging to surgically remove owing to their anatomical relationship. We previously reported on surgical treatment outcomes over a 10-year time frame. The purpose of this study was to update the OPHG clinical outcomes for cases in which chemotherapy has become the primary treatment option. The role of surgery was also revisited. METHODS: Patients with a diagnosis of OPHG who underwent treatment at Seoul National University Children's Hospital from February 1999 to July 2019 were included. A multidisciplinary approach was used to determine the patients' treatment plans. Chemotherapy was the first-line treatment for all patients. When symptoms of hydrocephalus existed, debulking surgery was performed to reopen the flow of cerebrospinal fluid. RESULTS: The study included 47 patients with OPHGs. The mean age was 6.9 years. Neurofibromatosis 1 was diagnosed in 3 patients. The extent of removal was none or biopsy in 13 (28%) cases, partial resection in 23 (49%) cases, and subtotal to gross total resection in 11 (23%) cases. In 32 (68%) patients, chemotherapy was first-line treatment. Ascites after ventriculoperitoneal shunt occurred in 3 cases, and 2 cases were successfully managed with debulking surgery. Treatment outcomes showed a 5-year overall survival rate of 97.7% and a 5-year progression-free survival rate of 47.7%. CONCLUSIONS: OPHG management using less invasive operations and chemotherapy as first-line treatment is feasible. Debulking surgery in patients with OPHGs may be considered in cases with cerebrospinal fluid pathway obstruction, progression despite chemotherapy or radiation, and refractory shunt-related ascites.
引用
- Kim JW, Phi JH, Lee JY, et al. Clinical Outcome of Optic Pathway and Hypothalamic Gliomas: A 20-Year Single-Institution Retrospective Study. World Neurosurg. 2022. PMID: 35840093. doi:10.1016/j.wneu.2022.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。